Drug Safety: Adverse Drug Reactions (ADR), Pharmacogenomics
Less than 5% of adverse drug reactions (ADRs) are reported to regulators, and equally alarming are estimates that more than 100,000 patients in the US alone die from ADRs each year.
ADRs are responsible for at least 10% of all hospital admissions, yet 95% are never reported to regulators. This lack of information on ADRs and drug safety is particularly significant for children, as more than 75% of all marketed drugs have never been clinically tested in children.
The POPi-led Canadian Pharmacogenomics Network for Drug Safety (CPNDS) represents a transdisciplinary consortium of experts from hospitals, universities, research institutes and Health Canada. The goal of CPNDS is to prevent ADRs in childhood by identifying predictive genomic markers for specific ADRs through active surveillance and pharmacogenomic research. CPNDS incorporates these markers into diagnostic tools that can be used to predict in whom serious ADRs are most likely before they occur. Alternative therapeutic recommendations can then be considered on the basis of a revised drug benefit/risk profile.
As of June 2018, 9,800 ADR cases and 88,500 matched controls have been enrolled from across 13 pediatric academic health centres in Canada (BC Children's Hospital, Alberta Children's Hospital, Stollery Children's Hospital, Winnipeg Health Sciences Centre, London Health Sciences Centre, Hospital for Sick Children, Children's Hospital of Eastern Ontario, McMaster Children's Hospital, Kingston General Hospital, Hopital Sainte-Justine, McGill University Health Centre, Janeway Children's Health Centre, IWK Health Centre).
For additional information on CPNDS please visit http://cpnds.ubc.ca/